A simple liquid chromatography-tandem mass spectrometry (LC-MS/MS) method has been developed and validated for simultaneous quantification of aripiprazole and its active metabolite, dehydroaripiprazole, in human plasma. Stable isotopically labeled aripiprazole, aripiprazole-D8, has been used as the internal standard (IS) for both analytes. Only 200 l of human plasma was needed for analyte extraction, using effective phospholipids-eliminating three-step microelution-solid-phase extraction (SPE, Oasis PRiME HLB 96-well Elution Plate). An ACE C18-PFP column was applied for chromatographic separation at 25
Introduction
Aripiprazole (ARI), a quinolinone derivative, is an atypical antipsychotic drug indicated in schizophrenia and schizoaffective disorder [1] . It displays a partial agonist/antagonist activity at dopamine D2 and D3 receptors and serotonine 5-HT1A receptors, whereas it acts as an antagonist at serotonine 5-HT2A receptors [2] .
ARI is metabolized to dehydro-aripiprazole (DARI), its main active metabolite, mainly by the cytochrome P450 (CYP) CYP3A4 and CYP2D6 isoenzymes. Both enzyme systems are subjected to drug interactions and genetic polymorphism, dose-adjustment is therefore necessary, especially when it is co-administered with CYP3A4 and CYP2D6 inhibitors or CYP3A4 inductors [3] . Additionally, allelic variants in ABCB1 and ABCG2 genes were found to influence the plasma concentrations of antipsychotics, including ARI. The ABCB1 2677TT/3435TT genotype has been linked to a significantly lower ARI plasma concentration/dose ratio if compared to patients carrying other ABCB1 genotypes [4] . Therefore, ARI plasma monitoring is suggested to improve efficacy, avoid drug-drug interactions or decrease adverse effects.
To date, numerous analytical methods have been used for ARI and DARI human plasma determination by high performance liquid chromatography (HPLC, also called 'LC') with ultraviolet detection (UV) and diode array detection (DAD) [5] [6] [7] . However, the lower limit of quantification (LLOQ) is lower or the run time is shorter in case of using LC-MS/MS methods with electrospray ionization (ESI). Despite improved sensitivity and selectivity of the LC-MS/MS-based methods, one of the main problems of ESI sources is the ion suppression or enhancement caused by the sample matrix (also known as a 'matrix effect') and interferences from metabolites [8] . Endogenous phospholipids cause ion suppression in both positive and negative ESI modes leading to matrix effect [9] and consequently increased variability and irreproducibility in bioanalytical LC-MS/MS methods. Lipids are the most variable components in human plasma. They can vary significantly among individuals according to diet and metabolic rate. However, glycerophosphatidylcholines, such as phosphatidylcholine, the main phospholipids circulating in the human plasma, constitute up to 70% of total plasma phospholipids [10] . Lysophospholipids, including lysophosphatidylcholine, compose up to 10% of total phospholipids [11] . Therefore, an optimization of an appropriated extraction method, which is able to eliminate phospholipids, combined with the use of stable isotopically labeled internal standards (SIL-IS) is extremely important in order to achieve reliable results and maintain the LC/MS-MS system clean [8, 12] .
Nonetheless, the majority of LC-MS/MS and ultra-LC-MS/MS (UHPLC-MS/MS) methods with ESI have used protein precipitation (PPT) or liquid liquid extraction (LLE) in addition to non SIL-IS instead of solid phase extraction (SPE) and stable SIL-IS [13] [14] [15] [16] [17] [18] . PPT is the fastest, but the least effective sample preparation technique, often resulting in significant matrix effects mainly due to the presence of endogenous phospholipids [11] . As follows, some HPLC-UV or LC-MS/MS methods choose SPE, including supported liquid extraction (SLE) [19] , a type of SPE, as an extraction method. Reversed-phase SPE methods are known to provide cleaner extracts and reduce matrix effects compared to PPT [11, 12, 20] . In spite of the fact that SPE has been applied in many published methods, it is characterized by longer performing times, need of evaporation, reconstitution steps and no usage of SIL-IS [20, 21] . Among all these methods, only studies employing SIL-IS based SPE [22] and SLE [19] were able to achieve the best results. Patel et al. also applied UHPLC, which offers shorter analyte separation time due to a higher pressure in the UHPLC system. However, none of the cited methods investigated phospholipids' elimination efficacy of the extraction method applied.
Thus, the aim of the present study was to develop a simple LC-MS/MS method based on effective phospholipids removing three-step microelution-SPE method compared to PPT for simultaneous plasma quantification of ARI and DARI as well as its further application to pharmacokinetic studies and clinical practice.
Materials and methods

Chemicals and reagents
ARI, DARI and SIL-IS [2H8]-ARI (ARI-D8) were provided by Toronto Research Chemicals (North York, Canada). Acetonitrile, methanol, ammonia solution (at 25%) and ammonia hydroxide 5N (HPLC Grade) were purchased from SYMTA (Madrid, Spain). Formic acid was supplied by Sigma-Aldrich (Madrid, Spain). All chemicals were analytical or LC-MS grade. The water for HPLC was obtained using a Milli-Q system (Millipore-Ibérica, Madrid, Spain). Blank human plasma samples from different individual human donors were supplied by the Transfusion Center of the Autonomous Community of Madrid (Madrid, Spain).
Stock solutions, calibration standards (CALs), and quality controls (QCs)
Stock solutions of CALs and QCs of ARI, DARI and ARI-D8 were prepared by dissolving an accurately weighed quantity in 0.5% formic acid solution in methanol to obtain a concentration of 1 mg/ml for all compounds. CALs were made from independent dilutions of each stock solution and spiked in the blank plasma to obtain 8 CALs with the concentrations of 0.18, 0.5, 1.0, 5.0, 25, 50, 100 and 120 ng/ml for ARI and 0.35, 0.5, 1.0, 2.5, 10, 50, 90 and 110 ng/ml for DARI. QC samples were prepared in the same fashion to obtain the four corresponding QC levels (LLOQ, low, medium, and high), as follows: 0.18, 0.5, 55, 110 ng/ml for ARI and 0.35, 0.7, 45, and 90 ng/ml for DARI. Secondary IS solution of 1000 ng/ml ARI-D8 was diluted 20 times to give a working solution of 50 ng/ml.
A drug-free blank plasma sample and a drug-free zero plasma sample (processed with IS) were included according to the recommendations for bioanalytical method validation of the US Food and Drug Administration (FDA) [23] , the European Medicines Agency (EMA) [24] and the International Conference on Harmonisation (ICH) [25] . All CALs, QC, and IS solutions were stored at −80 • C until use or analysis.
Chromatographic conditions
The HPLC system consisted of a 1200 Series separation module (Agilent Technologies, Madrid, Spain) controlled by Agilent MassHunter Workstation Data Acquisition software for programming samples and chromatographic conditions. Separations were carried out at 25 • C in an ACE C18-PFP column (3-m, 4.6 × 100 mm; SYMTA, Madrid, Spain) at 0.6 ml/min. The mobile phase consists of ammonium formate (5 mM, solvent A)-acetonitrile (solvent B) (pH 4.0; 65:35, v/v). The chromatogram was run under gradient condition as follows: initial conditions: 65% (A) and 35% (B); 0-0.1 min, gradually increasing eluent B to 75% (B); 0.1-0.5 min, gradually increasing eluent B to 90%; 0.5-1.5 min, gradually increasing eluent B to 99% and maintain from 1.5 to 3.0 min; 3.0-3.2 min returning to the initial conditions (65% A and 35% B) and maintain from 3.2 to 5.0 min. The chromatogram was followed by a re-equilibration time of 3.0 min. The volume injected into the HPLC was 5 l. 
Mass spectrometry
The mass spectrometry detection system consisted of an Agilent Technologies 6410B, triple quadrupole with ESI in positive ion mode. The mass spectrometry measurement was operated in multiple-reaction monitoring (MRM) mode. The desolvation gas (nitrogen) and flow is operated at 350 • C and 12 l/min, respectively. The nebulizer pressure was 60 psi and the capillary voltage was 5 kV. The MS collision gas was highly pure N2 (>99.9995). The dwell time, fragmentor voltage and collision energy were optimized under selected ion monitoring (SRM) for all the compounds (Table 1) . After separation by HPLC, the peak area corresponding to the mass-to-charge ratio (m/z) transition for the quantifier ion was measured as relative to the m/z transition for its IS. The m/z transition for the qualifier ion was also monitored to add specificity to the results. Additionally, monitoring of m/z 184 > 184 as a common insource collision-induced dissociation (CID) ion fragment produced by endogenous phospholipids, glycerophosphocholines, was used [26] (Table 1 ). The integration peak area of the MRM transitions of each analyte was calculated using MassHunter Workstation Quantitative Analysis software (Agilent Technologies, Madrid, Spain).
Sample preparation
For sample clean-up, two different types of extraction were tested in order to check phospholipids' elimination capacity. Therefore, to choose the best sample preparation method, twelve different plasma samples were extracted using simple PPT or threestep microelution-SPE. For PPT, 200 l of plasma sample was spiked with 10 l of IS and 800 l of precipitating agent, acetonitrile with 1% formic acid (4:1, v/v) and centrifuged at 14000 rpm and 4 • C for 5 min. Then the supernatant was evaporated to dryness using a concentrator (5301, Eppendorf, Germany) at 45 • C for 1 h and 15 min. Consequently, the dry residue was reconstituted with 200 l of the acetonitrile/methanol/buffer (ammonium formate, 5 mM at pH 4.0) reconstitution solution (8:1:1, v/v/v) and 5 l of sample was injected into the LC-MS/MS system.
On the other hand, Oasis PRiME HLB (hydrophilic-lipophilic balance) 96-well Elution Plate, 3 mg Sorbent per Well (Waters, Madrid, Spain) was used for SPE of the analytes. Sample preparation was fast and simple. Microelution-SPE consisted of only three-steps: sample loading, washing and elution. 200 l of plasma sample was spiked with 10 l of IS and 290 l of 0.2% formic acid, pH 2.0, and loaded (2 × 250 l) into the Elution Plate. Next, a washing step with 400 l (2 × 250 l) of 5% methanol solution in MilliQ water and addition of 2% ammonia was applied. Vacuum between 5 and 15 mmHg was applied in each step of the SPE process. Elution was performed with 200 l (2 × 100 l) of acetonitrile/methanol/buffer (ammonium formate, 5 mM at pH 4.0) solution (8:1:1, v/v/v) and collected in a 1 ml 96-well plate (Agilent Technologies, Santa Clara, USA). Then, 5 l of eluate was directly injected into the LC-MS/MS system without evaporation and reconstitution. Finally, SPE was chosen as sample preparation for method validation.
Assay validation procedures
The method was validated according to the recommendations published online by the FDA [23] , EMA [24] and ICH [25] .
Calibration curve, selectivity and LLOQ
Quantitative analysis of ARI and DARI in plasma was carried out using the method of IS. Eight CALs were used for validation to cover the range of clinically relevant concentrations expected in most of the healthy volunteers. A quadratic regression was used to calculate the equation related to the area ratio of each analyte versus IS to the concentration of the analytes in the CALs. Weighting factor of 1/x was used to obtain the best fit for all CALs. Six standard curves from different days were analyzed. To fulfill validation criteria, the error of accuracy and coefficient of variation (CV) should not exceed 15% for all CALs, except for the LLOQ (<20%). To be considered LLOQ, the extraction ion chromatogram (XIC) peak area ratio of each analyte should be at least 5 times higher than that of the blank.
The selectivity of the method was studied by analyzing blank plasma samples from 6 different individual human donors, with the addition of IS (zero plasma) or without the IS. The method is considered selective, when the XIC peak area ratio is less than 5 times of the LLOQ for ARI and DARI, and less than 20 times for the IS.
Precision and accuracy
The precision and accuracy of the method were evaluated by analyzing 6 replicates per 4 concentration QCs levels (LLOQ and low, medium, and high) in a single analytical run that covered the calibration curve range. The intra-day precision and accuracy were assessed by analyzing a single analytical run in a single day. The inter-day variation was evaluated over 3 analytical runs from 3 different days. Precision was measured as a CV (%) and accuracy as the percentage difference between the theoretical and the measured concentration according to the following equation:
To verify precision and accuracy, the error must be less than 15% for all samples except the LLOQ (<20%).
Extraction recovery and matrix effect
Recovery is measured as the ratio of the compound concentration (relative) or XIC peak area (absolute) in plasma following SPE (pre-extracted sample) to the same analyte concentration spiked directly in blank plasma sample that had undergone the process of SPE (post-extracted sample). The matrix effect of human plasma was evaluated by comparing the ratio of the compound concentration (relative) or XIC peak area (absolute) in post-extracted sample to the pure solution of the analyte. Pure solution of the analyte was obtained by the addition of the same amount of analyte to the final elution solution [acetonitrile/methanol/buffer, pH 4.0 (8:1:1, v/v/v)], which had not undergone the extraction process.
In both tests six repetitions of the LLOQ, low QC and high QC were analyzed in at least blank plasma samples from 6 different individual human donors for all analytes. The recovery of QC samples had to be precise, reliable, and reproducible. To validate the matrix effect, the CV should not exceed 15% for all the QCs and less than 20% for LLOQ. All recovery and matrix effect values were calculated as absolute and relative to its IS.
Stability
The stability of ARI and DARI at different conditions has been already evaluated in many articles. However, we conducted the following assays at low and high QC (4 replicates each) for ARI and DARI to check the stability of the analytes in our laboratory conditions:
-in the human plasma samples: after 24 h at room temperature and at 4 • C in the fridge; after 3 cycles of freeze-thaw in the freezer at −80 • C -in the human plasma sample extract: after 24 h at 19 • C in the autosampler.
Analyte stability need not to be 100%, but it had to be between 85 and 115% and CV should be less than 15% for all the QCs studied.
Carry-over
Carry-over was evaluated by injecting blank samples after CAL at the highest concentration. The XIC peak area of blank sample injected after CAL at the upper limit of quantification could not exceed 20% of the LLOQ and 5% of the IS XIC peak area. To prevent carry-over the needle was washed 5 times between injections (vial and flash port) with water and acetonitrile solution (50:50, v/v).
Application of the method to pharmacokinetics of ARI and DARI in healthy volunteers
Our method was successfully applied to pharmacokinetic analysis of 1133 samples from 103 healthy volunteers who received a single oral dose of ARI (10 mg) in several bioequivalence studies under fasting conditions. Blood samples were taken at the following time intervals after dosing: 0, 1, 2, 4, 6, 8, 10, 12, 24, 48 and 72 h. Blood samples were collected in EDTA dipotassium dihydrate (EDTA K2) tubes (Vacuette, Madrid, Spain) and centrifuged at 3500 rpm for 10 min at 4 • C. The plasma was separated and stored at −20 • C. The study was approved by the local ethics committee (Clinical Research Ethics Committee of "Hospital Universitario de la Princesa", Madrid, Spain), and informed consent was obtained from the healthy volunteers. Pharmacokinetic parameters were estimated by noncompartmental analysis using WinNonLin Professional Edition, version 2.0 (Scientific Consulting, Inc., Cary, NC). Maximum plasma concentration (C max ) and time to C max (T max ) were determined directly from plasma concentration data. The area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUC 0-t ) was calculated using the trapezoidal method. The half-life (T 1/2 ) was calculated as ln2/ke, the apparent terminal elimination rate, which was estimated by long-linear regression from the terminal portion of the log-transformed concentration-time plots.
Results and discussion
Optimization of MS/MS conditions and chromatography
The full scan spectra in positive ESI mode indicated that all analytes were protonated molecules [M+H] + which were therefore selected to detect the most abundant products. Fig. 1 shows the percentages of abundance of the precursor and product ions of the quantifier, qualifier, or IS versus mass to charge (m/z) for ARI (A) DARI (B) and ARI-D8 (C) under SRM and the fragmentation pattern of quantifier transition. Table 1 summarizes all the optimized mass spectrometer parameters, such as the transition in SRM mode, dwell time, fragmentor voltage and collision energy for each analyte (quantifier and qualifier ion) and the IS. For each analyte, a second transition named qualifier ion was optimized to confirm the analysis. Qualifier ratio, the ratio of qualifier ion/quantifier ion of ARI and DARI, has been monitored for CALs, QCs and real samples and has been constant through the analysis.
The chromatographic separation was run under gradient conditions to reach better resolution of the three compounds. Fig. 2 displays a typical XIC of a blank human plasma (A), pure solution (B) and blank human plasma spiked with LLOQ before (pre-extracted sample, C) and after SPE (post-extracted sample, D) of both, ARI and DARI. The retention times (tR) were very consistent throughout the recordings ( Table 1 ). The tR was 3.644 min, 3.451 min and 3.582 min for ARI, DARI and ARI-D8, respectively. Thus, the tR of ARI and DARI were very similar. Although the complete analyte separation was not achieved, despite the ICH guideline requirements [25] , proper MS detector settings (MRM mode) have been applied to prevent detector-side selectivity. For MS analysis, it is a commonly described phenomenon that due to the presence of 8 deuteriums, the IS (ARI-D8) elutes significantly earlier than unlabeled ARI. Therefore, the different elution times between ARI-D8 and the compounds of interest (ARI and DARI) prevent fully compensation of the ionization effects. Based on these facts, an effective phospholipids' removing SPE clean-up method has been applied to ensure the success of the present assay design. The recording time was 5 min followed by 3 min for re-equilibration owing to gradient elution.
Due to the similarities of ARI and its metabolite, the chromatographic separation seems to be complicated. However, when large sample amount for clinical pharmacokinetic studies is processed, the time of analysis of a single sample is extremely important. Thus, XBridge BEH C18 column (2.5-m, 2.1 × 75 mm) and ACE C18-pentafluorophenyl (PFP) column (3-m, 4.6 × 100 mm) were applied to separate both of the analytes under the same mobile phase conditions. Based on our results, we have chosen C18 column with PFP group for analyte separation. Due to -interactions with the aromatic ring and NH2 groups, ACE C18-PFP column has a better resolution and improves analyte separation compared to ordinary C18 column. Our total chromatographic run lasted 8 min, similar to other authors [13] . Although shorter analytical runs ranging from 1.2 min to 7.5 min exist [15, 22] , there are mostly isocratic separations, which tend to cause problems in repeatability in retention time, XIC peak area and peak height or linearity of the calibration curve [27] .
Another important factor to consider is the injection volume. Taking into account the particle size of the column, we have injected 5 l of the sample into the LC-MS/MS system. On the contrary, several LC-MS/MS methods have used larger injection volume ranging between 20-100 l [14, 15, 20] , which can cause carry-over effect and shorter the analytical column life-time.
Calibration curve, selectivity and LLOQ
The method was linear in the range of 0.18-120 ng/ml for ARI and 0.35-110 ng/ml for DARI. The correlation coefficient (R 2 ) values were 0.9979 ± 0.0026 for ARI and 0.9995 ± 0.0004 for DARI (n = 6). We obtained satisfactory R 2 , similar to other methods [13, 15, 17] . Our calibration range was adjusted according to the real samples' concentration (55.72 ± 14.58 ng/ml for ARI and 7.01 ± 2.44 ng/ml for DARI), enabling us to obtain pharmacokinetic data for both ARI and its metabolite.
The present method was selective, as no significant interference was found in the detection of ARI and DARI in the absence or presence of the IS in 6 different blank samples. Fig. 2 shows the selectivity of the method. Fig. 2A displays an XIC of blank sample, while Fig. 2B, 2C and 2D shows ARI and DARI at LLOQ concentration, sample. LLOQs XIC peak area ratio is 5 times higher than the one of the blank sample and remained at similar concentrations in pure solution, in pre-extracted and post-extracted sample, corroborating the selectivity of the method.
The LLOQs of 0.18 ng/ml for ARI and 0.35 ng/ml for DARI presented adequate intra-and inter-day accuracy and CV values ( Table 2 ). The analyte XIC area/blank area ratio was 18.03 ± 13.60 for ARI and 12.82 ± 8.19 for DARI, being more than 5 times higher than that of any blank plasma. The XIC area of the zero plasma, Table 2 Intra-and inter-day precision and accuracy assays. Data were obtained from 4 quality controls (QCs) −the lower limit of quantification (LLOQ), low, medium and high − on the same day as intra-day and on 3 consecutive days as inter-day precision and accuracy assays. Precision data are expressed as the percentage of the coefficient of variation (CV) for repeated measurement and accuracy as the percentage of the closeness of theoretical concentration to the measured value present in the matrix. The corresponding concentrations are displayed as the mean ± standard deviation (SD) of the number of total experiments is shown in parenthesis.
Compound
Concentration Intra-day (n = 6) Inter-day (n = 18) (ng/mL) Mean ± SD (ng/mL) CV (%) Accuracy (%) Mean ± SD (ng/mL) CV (%) Accuracy (%) Table 3 Extraction recovery and matrix effect tests. Recoveries and matrix effect are expressed as absolute and relative (to their stable isotope-labeled internal standard) values. Averaged data are given as the percentage of the mean recovery/matrix effect ± standard deviation (SD) and coefficient of variant (CV) of the total number shown in parenthesis of the lower limit of quantification (LLOQ), and low and high quality controls (QCs).
Compound Concentration (ng/mL) Recovery (n = 6) Matrix effect (n = 6) with its IS, was 20 times larger than the area of the blank plasma (725.04 ± 212.14 for both, ARI and DARI). To date, the lowest LLOQs were obtained by Patel et al. [22] with the value of 0.05 ng/ml for ARI and by Song and colleagues [17] with the value of 0.01 ng/ml for DARI. While not reaching the before-mentioned values, we still outperformed other UHPLC-and LC-MS/MS methods developed by different authors [14, 16, 18, 20, 21] . Table 2 summarizes the results for precision and accuracy with standard deviation (SD), CV and accuracy calculated for each sample. The intra-and inter-day precision was optimal with CV less than 11% and accuracy lower than 10%. These results are similar to those obtained by Song and his group [17] and better comparing to Kubo et al. [15] and Choong and co-workers [21] . Thus, the method is reproducible and accurate for ARI and DARI.
Precision and accuracy
Extraction recovery, matrix effect and phospholipids removal
The extraction recovery and matrix effect were determined at three concentration levels: LLOQ, low and high QC. Table 3 summarizes the results for absolute and relative extraction recoveries and matrix effects in percentages (100% is referred as 100% of recovery/no matrix effect) with mean and CV values calculated for each sample. The absolute mean recoveries were found between 88% and 96% for both compounds, as well as for IS. However, the relative recovery values were more desirable compared to absolute values, as they have been achieved between 96% and 106% for ARI and DARI. We have achieved appropriate values of absolute mean matrix effect for all compounds (between 90% and 100%). The relative mean of matrix effect was in the range of 92% to 105%. Therefore, the extraction procedure was accurate and reproducible, no significant matrix effect was observed with CV values which were less than 9% in all cases.
Extraction procedure applied in the present work enables direct sample injection into the LC-MS/MS without evaporation and reconstitution process. Three-step microelution-SPE applied for sample preparation and the use of SIL-IS enables decreasement of matrix effect and improves assay selectivity, which is similar to that reported by Patel et al. [22] . However, most of the methods employed PPT or LLE, which are not efficient in eliminating phospholipids, surfactants, salts [11] and may interfere with ionization process and consequently producing the loss of the analyte signal [28] . Accordingly, our extraction recovery is more efficient (between 96% and 106%) than other methods applying PPT or LLE as sample preparation. The main recoveries reported in the bibliography [5, 6, 20, 21] , which used PPT or LLE methods, were ranging from 69% to 123%. Moreover, in spite of large impact of matrix effects in LC-MS/MS analysis [29] , this effect has not been taken into account in some of previously described methods [14, 15] . Matrix effects' evaluation is usually based on the post-column infusion method [16] or the post-extraction addition method [18] , similar to our assay. The advantage of post-extraction addition method over postcolumn infusion method is the quantitative and not qualitative estimation of ionization suppression/enhancement. Consequently, our results on matrix effects were among the best achieved in the bibliography, similar to those achieved by Patel et al. [22] and De Meulder and co-workers [19] . Patel et al. used SPE as well, but with UHPLC-MS/MS system, which is known of producing less matrix effects due to smaller injection volume and lower flow rates.
To compare our results on phospholipids removal with previously published literature, we have tested twelve human plasma samples with SPE and PPT extraction methods. PPT using organic solvents has been shown to yield the highest degree of matrix effects in comparison with SPE [9] . Thus, it has been used as a positive control of phospholipids' content comparing to SPE. Due to the amphiphilic characteristic of phospholipids, the application of hydrophilic-lipophilic SPE sorbent enabled us to remove efficiently 99.45% endogenous plasma phospholipids compared to PPT method (100.00 ± 11.16% vs 0.55 ± 0.47%, p < 0.001). Fig. 3 displays endogenous plasma phospholipids' content in percentages using PPT or microelution-SPE, respectively. Additionally, we were able to chromatographically separate phospholipids (tR = 1.477 min) from analytes elution (ARI, tR = 3.644 min; DARI, tR = 3.451 min and ARI-D8, tR = 3.582 min). Monitoring of phospholipids was useful in method development to avoid the matrix interferences without negative influence on analyte quantification. This is the first report monitoring simultaneously human plasma ARI, DARI and phospholipids in the same acquisition LC-MS/MS method. Table 4 summarizes the results of stability assays at low and high QC for ARI (0.5 and 110 ng/ml) and DARI (0.7 and 90 ng/ml). The short-term stability of both analytes after 24 h at room temperature ranged from 87% to 96%, with CV values in the range of 0%-4%. The stability test after 24 h at 4 • C in the fridge also showed a range of 91% and 99% (CV no higher than 7%). The stability tests after 3 freeze-thaw cycles in the freezer at −80 • C showed no significant degradation, with stability in the range of 90%-101% and CV in the range of 1-5%. Finally, the stability after 24 h at 19 • C in the autosampler revealed values in a range of 100%-108% (CV does not exceed 5%). The mean stability of the analytes was close to 100% and the CV was less than 7% in all cases.
Stability
The EMA guideline stresses that analyte stability cannot be proven by literature data [24] , further outlining the importance of analyte stability testing. The instability of the analyte and its decomposition influences the precision and accuracy of the procedure and is, thus, accounted for by these two parameters [30] . Therefore, we guaranteed stability of the analytes during sample preparation, the analytical process, and the storage conditions, similar to other authors [21, 22] . In spite of its importance, methods without evaluating stability tests are present in the bibliographic data [13] .
Carry-over
The carry-over in the blank sample following after CAL at highest concentration was 14.31% ± 4.45% of the LLOQ for ARI and 13.71% ± 8.56% for DARI, less than 20%; for IS was 0.01%, less than Table 4 Stability tests. Storage stability of aripiprazole and dehidro-aripiprazole at low and high concentration in the human plasma sample after 24 h at room temperature, 24 h at 4
• C in the fridge, 3 freeze-thaw cycles (-80
• C) and in the human plasma samples extract after 24 h at 23
• C in the autosampler. Results are given as mean percent difference from theoretical concentration ± standard deviation (SD). The total number of experiments is shown in parenthesis.
Compound
Concentration Room Temperature (24 h) Fridge (24 h) Freeze-thaw (3rd cycle) Autosampler (24 h) (ng/mL) (n = 4) 5%. Thus, in line with EMA regulations, no significant carry-over effect was observed. Despite the fact that evaluation of carry-over effect is not mandatory in all guidelines for bioanalytical methods, such as in International Conference on Harmonisation (ICH) [25] or FDA guidelines [23] , it should be assessed within the method development and validation. Determination of carry-over effect is a very simple way to detect a possible column contamination after injection of high concentrated CALs and can be included routinely in each analytical run. Unfortunately, the carry-over effect was only evaluated by few authors [18, 21, 22] , showing excellent results.
Application of the method to pharmacokinetics of ARI and DARI in healthy volunteers
This procedure has been successfully applied to several bioequivalence studies. Fig. 4 displays XICs of real samples from healthy volunteers before (A) and after (B and C) a single oral administration of ARI (10 mg). Panel A of Fig. 4 shows an example of the blank real sample for ARI and DARI. Panel B represents chromatographic peaks of ARI and DARI 1 h after ARI administration and panel C demonstrates ARI and DARI concentration at the time points (2 h for ARI and 48 h for DARI) closest to the maximum concentration (C max ) calculated with WinNonLin (3.25 h for ARI and 52.71 h for DARI, respectively). (C max of ≈50 ng/ml), who used the same single oral dosage. Other authors have reported different levels of C max due to higher-30 mg [6] or lower administration dose of 5-6 mg [5, 17] . In addition to a different dose, the variability in pharmacokinetic results is caused by the use of distinct populations (Caucasian, Chinese and Indian) as well as the comparison of healthy volunteers versus patients. It was not possible to calculate the T 1/2 of DARI as the last sample was taken at 48 h instead of 72 h as EMA guidelines requires for long half-life drugs [24] .
Conclusion
In summary, the present method is fast and simple and easily applicable to a large sample number. The method is linear and covers a wide range of the concentration curve from 0.18 to 120 ng/ml for ARI and from 0.35 to 110 ng/ml for DARI. This LC-MS/MS assay is precise, accurate, sensitive, specific, stable and is not showing significant carry-over effects according to FDA, EMA and ICH recommendations and is currently being applied in pharmacokinetic studies. The present method applies effective phospholipids' removal and therefore results in excellent recoveries and no significant matrix effect, thanks to the three-step microelution-SPE sample preparation method and the usage of SIL-IS.
